Bohdan Kadlec

The incidence and predictors of thromboembolic events in patients with lung cancer.

Patients with lung cancer experience elevated risk of venous thromboembolism. Cancer patients with thrombosis have a shorter life expectancy and the occurrence of VTE worsens the quality of life and may delay, interrupt, or completely halt the cancer therapy. In a large cohort of lung cancer patients we monitored the incidence of venous thromboembolism and we identified groups of patients with the highest risk of venous thromboembolism suitable for antithrombotic prophylaxis, which could favourably affect their morbidity and mortality.

Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients

Background: The purpose was to evaluate the activity and feasibility of CBDCA together with NVBO in 1st line treatment NSCLC patients. Conclusions: The treatment with NVBO and CBDCA was well tolerated with evidence of high antitumour activity. This combination was active in all groups patients according histology.

Intravenous vinorelbine (NVBiv) on D1 and oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first-line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonselected population.

The use of intravenous vinorelbine (NVBiv) on D1 and oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first-line treatment in advanced non-small lung cancer (NSCLC) patients: results of a prospective study in nonselected population are reported.

59P MARKERS OF PROLIFERATION ACTIVITY IN NON-SMALL CELL LUNG CANCER

A variety of parameters acknowledged to be markers of proliferation activity of non-small cell lung cancer were followed up and discussed in this paper.

6 Chemotherapy with paclitaxel, carboplatin and concurrent radiotherapy for advanced non small cell lung cancer

The authors report the results of a paclitaxel-caboplatin study in patients with advanced non small cell lung cancer with concurrent radiotherapy.

P-921 The 5-years results of the surgical treatment in patients with non-small cell lung cancer (NSCLC): An analysis of 540 patients

The 5-years results of the surgical treatment in patients with non-small cell lung cancer (NSCLS): An analysis of 540 patients